Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Convertible Debt (2020 - 2021)

ProQR Therapeutics' Convertible Debt history spans 2 years, with the latest figure at $17.2 billion for Q1 2021.

  • On a quarterly basis, Convertible Debt changed N/A to $17.2 billion in Q1 2021 year-over-year; TTM through Mar 2021 was $17.2 billion, a N/A change, with the full-year FY2020 number at $16.5 billion, changed N/A from a year prior.
  • Convertible Debt hit $17.2 billion in Q1 2021 for ProQR Therapeutics, up from $16.5 billion in the prior quarter.
  • Over the last five years, Convertible Debt for PRQR hit a ceiling of $17.2 billion in Q1 2021 and a floor of $16.5 billion in Q4 2020.